UNSPSC 51284017: Tetracycline

This classification denotes a tetracycline antibiotic with the molecular formula C22H24N2O8, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier F8VB5M810T, chemically known as 2-naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4s,4as,5as,6s,12as)- but generally known as tetracycline, which bears US NIH Compound Identifier 5280962.

UNSPSC 51284017 Tetracycline, a Commodity code, is poorly aligned with the recent state and local solicitation activity tagged under it—the code nominally names a specific antibiotic pharmaceutical, but the opportunities posted against this code address naloxone, safe drug deactivation systems, fire-rescue medical supplies, and multi-source generic pharmaceuticals and OTC products. The mismatch suggests either misclassification in the source system or that this code sits within a broader pharmaceutical procurement taxonomy that state and local buyers are using to tag diverse medical and pharmaceutical procurement. Where the code appears in recent opportunities, state and local agencies are purchasing finished medical products and pharmaceutical supplies rather than raw tetracycline active pharmaceutical ingredient. Issuing bodies span county health systems (Seminole County, Florida), state HHS commissions (Texas), municipal fire departments (City of Tampa), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent activity concentrated in Florida, Texas, and Minnesota. The City of Tampa's IFB for medical and first aid supplies targeting the Fire Department Rescue Division (Bid 26P00145, due March 13, 2026, estimated value $700,000.00) and Seminole County's IFB for naloxone and safe drug deactivation systems (IFB60459723LAS, due July 26, 2023) represent direct-buy opportunities for finished goods with defined unit quantities and fixed delivery schedules. The Texas HHS Commission's RFI on Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions (HHS0017013, response due April 3, 2026) and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, proposals due March 26, 2026) signal larger-scale procurement vehicles serving multiple jurisdictions. Tampa's procurement is designated as a sheltered market for certified Small Local Business Enterprises with a 5 percent bid discount, while the others show no explicit set-aside restrictions in available documentation. No recent opportunities directly name tetracycline as a specified product line.